Resolution based on the results of the Advisory Board on Optimizing the NTRK diagnostic algorithm, Moscow, January 30, 2021

doi:https://doi.org/10.17116/patol20218305171

References:

Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, Jungbluth AA, Zehir A, Benayed R, Drilon A, Hyman DM, Ladanyi M, Sireci AN, Hechtman JF. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33(1):38-46. https://doi.org/10.1038/s41379-019-0324-7
Rolfo CD, De Braud FG, Doebele RC, Drilon AE, Siena S, Patel M, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Goto K, Lee J, Bazhenova L, John T, Fakih M, Simmons BP, Pitcher B, Huang X, Demetri GD. Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis. J Clin Oncol. 2020;38(15 suppl):3605. https://doi.org/10.1200/JCO.2020.38.15_suppl.3605
Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P. Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor. J Med Chem. 2016;59(7):3392-408. https://doi.org/10.1021/acs.jmedchem.6b00064
Fischer H, Ullah M, de la Cruz CC, Hunsaker T, Senn C, Wirz T, Wagner B, Draganov D, Vazvaei F, Donzelli M, Paehler A, Merchant M, Yu L. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro Oncol. 2020;22(6): 819-829. https://doi.org/10.1093/neuonc/noaa052
John T, Chiu CH, Cho BC, Fakih M, Farago AF, Demati GD, Goto K, Deebele RC, Siena S, Drilon A, Patel MR, Liu SV, Ahn MJ, Bazhenova L, Overbeck TR, Nieva J, Kim SW, Veronese L, Day BM, De Brand F. 3640 Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases. Ann Oncol. 2020;31(4 suppl):397-398. https://doi.org/10.1016/j.annonc.2020.08.473
Dziadziuszko R, Siena S, Tan DSW, Cho BC, Ahn MJ, Goto K, Carrido-Lopez P, Farago AF, Loong HHF, Tosi D, John T, Wolf J, Chiu CH, Liu SV, Patel MR, Drilon A, Pitcher S, Simmons S, Deebele RC. 1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline. Ann Oncol. 2020;31(4 suppl):833-834. https://doi.org/10.1016/j.annonc.2020.08.1602
Robinson G, Desai A, Basu E, Foster J, Gauvain K, Sabnis A, Shusterman S, Macy M, Mease L, Yoon JM, Cash T, Abdelbaki MS, Nazemi KJ, Pratilas C, Weiss B, Chohan S, Cardenas A, Hutchinson K, Bergthold G,. Gajjar A. HGG-01. Entrectinib in recurrent or refractory solid tumors including primary CNS tumors: updated data in children and adolescents. Neuro Oncol. 2020;22(3 suppl):iii344. https://doi.org/10.1093/neuonc/noaa222.293
Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, López-Rios F, Douillard JY, Andrè F, Reis-Filho JS. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30(9):1417-1427. https://doi.org/10.1093/annonc/mdz204
Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, Arcila ME, Dogan S, Klimstra DS, Ladanyi M, Jungbluth AA. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41(11):1547-1551. https://doi.org/10.1097/PAS.0000000000000911
VENTANA pan-TRK (EPR17341) Assay Package Insert, 2018.
Conde E, Hernandez S, Sanchez E, Regojo RM, Camacho C, Alonso M, Martinez R, Lopez-Rios F. Pan-TRK immunohistochemistry an example-based practical approach to efficiently identify patients with NTRK fusion cancer. Arch Pathol Lab Med. 2021;45(8):1031-1040. https://doi.org/10.5858/arpa.2020-0400-RA
Preobrazhenskaya EV, Iyevleva AG, Suleymanova AM, Tiurin VI, Mitiushkina NV, Bizin IV, Ivanstov AO, Gorustovich OA, Shelekhova KV, Kachanov DY, Varfolomeeva SR, Roschin VY, Kazakova AN, Litvinov DV, Shamanskaya TV, Savelov NA, Suspitsin EN, Imyanitov EN. Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors. Pediatr Blood Cancer. 2020;67(5):e28220. https://doi.org/10.1002/pbc.28220
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491-1505. https://doi.org/10.1016/j.annonc.2020.07.014
Yoshino T, Pentheroudakis G, Mishima S, Overman MJ, Yeh KH, Baba E, Naito Y, Calvo F, Saxena A, Chen LT, Takeda M, Cervantes A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard JY. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol. 2020;31(7):861-872. https://doi.org/10.1016/j.annonc.2020.03.299
Sidorov IV, Kletskaya IS, Konovalov DM. Secretory carcinoma of the salivary gland (mammary analogue secretory carcinoma) in children. Arkhiv Patologii. 2020;82(2):43-51. https://doi.org/10.17116/patol20208202143
https://doi.org/10.17116/patol20208204147 https://doi.org/10.17116/patol20208204147
https://doi.org/10.17116/patol20208204153 https://doi.org/10.17116/patol20208204153
Elfving H, Broström E, Moens LNJ, Almlöf J, Cerjan D, Lauter G, Nord H, Mattsson JSM, Ullenhag GJ, Strell C, Backman M, La Fleur L, Brunnström H, Botling J, Micke P. Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer. Lung Cancer. 2021;153:53-59. https://doi.org/10.1016/j.lungcan.2020.11.023